Investment case
Onco360
ONCS · 2 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 2 macro, policy, and market developments to Onco360 since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ONCS yet, so no modelled value is shown. The ONCS valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ONCS on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
Increased prescription volume and dispensing fees from being the national specialty dispensing partner for a newly approved oncology drug.
· Moves revenue growth rate, profitability margins from new drug distribution
What changed, by assumption
- 2026-08-27FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer | Bullish | 1-3m | 0.60 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer | Bullish | 1-3m | 0.60 |